The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 01, 2022

Filed:

Nov. 05, 2015
Applicants:

The Regents of the University of California, Oakland, CA (US);

United States Government Represented BY the Department of Veterans Affairs, Washington, DC (US);

Inventors:

Steven M. Dubinett, Los Angeles, CA (US);

Sherven Sharma, Culver City, CA (US);

Jay M. Lee, Los Angeles, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/15 (2015.01); A61K 39/00 (2006.01); C07K 14/52 (2006.01); A61K 38/19 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/24 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/521 (2013.01); A61K 9/0019 (2013.01); A61K 38/195 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61P 35/00 (2018.01); C07K 16/24 (2013.01); C07K 16/249 (2013.01); C07K 16/2818 (2013.01); C12N 7/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01); C12N 2710/10041 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10071 (2013.01);
Abstract

The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal in combination with a checkpoint inhibitor, including monoclonal antibodies and small molecule inhibitors. Exemplary checkpoint molecules include CTLA-4, a CTLA-4 receptor, PD-1, PD1-L1, PD1-L2, 4-1BB, OX40, LAG-3, TIM-3 or a combination thereof. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.


Find Patent Forward Citations

Loading…